Credit Suisse Group AG reiterated their outperform rating on shares of Shire PLC (LON:SHP) in a research report sent to investors on Friday morning. Credit Suisse Group AG currently has a GBX 5,200 ($64.36) price target on the biopharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on SHP. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,600 ($69.31) target price on shares of Shire PLC in a research report on Monday, June 13th. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a research report on Tuesday, June 14th. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a research report on Wednesday, June 15th. BNP Paribas reissued an outperform rating and issued a GBX 5,700 ($70.54) price target on shares of Shire PLC in a report on Wednesday, June 15th. Finally, HSBC reissued a buy rating and issued a GBX 5,400 ($66.83) price target on shares of Shire PLC in a report on Friday, July 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of GBX 5,828 ($72.13).
Shire PLC (LON:SHP) opened at 5171.00 on Friday. The stock’s market capitalization is GBX 35.31 billion. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The firm has a 50 day moving average price of GBX 5,001.78 and a 200 day moving average price of GBX 4,587.48.
The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were given a GBX 3.51 ($0.04) dividend. This represents a yield of 0.07%. The ex-dividend date was Thursday, September 8th.
In other Shire PLC news, insider Dominic Blakemore bought 133 shares of the stock in a transaction that occurred on Friday, September 30th. The shares were purchased at an average cost of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.